Fulcrum Therapeutics
NEWS
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
There was still some carryover from the European Society of Medical Oncology Congress 2021, but there was plenty of other clinical trial news last week. Here’s a look.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
There was plenty of clinical trial updates last week. Here’s a look.
Fulcrum achieved what the company is calling a clinical first. Data showed that using losmapimod slowed the progression of FSHD and demonstrated improved function in patients.
It was a moderately busy week for clinical trial news. Here’s a look.
It was a busy week for clinical trial updates. Here’s a look.
Shares of Fulcrum Therapeutics were up more than 14% in premarket trading after the company announced it will begin the Phase LOSVID III study to assess losmapimod as a potential treatment of COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 10, 2020.
JOBS
IN THE PRESS